|
| Reevaluation of systematic reviews on Danhong Injection in the treatment of acute cerebral infarction |
| Hits 33 Download times 11 Received:October 04, 2024 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2025.03.09 |
| Key Words
Danhong Injection;acute cerebral infarction;systematic review;overview of systematic review;evidence based medicine |
| Author Name | Affiliation | E-mail | | ZHU Zheng | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China
National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China | | | WANG Keyi | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHAO Xia | Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050013, China | | | ZHANG Yazi | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | CHEN Bo | Experimental Acupuncture Research Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | YANG Fengwen | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | 13682027022@163.com |
|
| Abstract
|
| [Objective] To evaluate the systematic review/Meta methodology quality of randomized controlled trials of Danhong Injection in the treatment of acute cerebral infarction，and to ebaluate the methodological quality and the status of clinical evidence. [Methods] Systematic review of randomized controlled trials of Danhong Injection in the treatment of acute cerebral infarction were searched in The Chinese Fulltext Journal Database（CNKI），Wanfang Data，SinoMed，PubMed，EMbase and the Cochrane Library databases from inception to June 2023. The AMSTAR2 scale was used to evaluate the methodological quality of the included systematic reviews，and the results of the systematic reviews were summarized. [Results] Fourteen systematic reviews of Danhong Injection in the treatment of acute cerebral infarction were included. The results showed that Danhong Injection could improve the clinical effective rate，neurological deficit score and activities of daily living in patients with acute cerebral infarction，and no serious adverse reactions were reported. It was found that the quality of systematic reviews of the included randomized controlled trials was extremely low，all systematic reviews did not report key item 2 and key item 7，and the bias risk assessment method used in the included studies was unreasonable. All systematic reviews failed to report non-critical items 3，10，and 16，namely to explain the choice of study design，to report information on the funding of the systematic review，and to report sources of potential conflicts of interest. [Conclusion] The published systematic evaluation results of Danhong Injection in the treatment of acute cerebral infarction showed that Danhong Injection alone or in combination can improve the clinical effective rate，improve the neurological deficit function score and daily living ability of patients with acute cerebral infarction，and has good safety. However，due to the low overall quality of the original study and systematic review，the reliability of the results is affected，and high-quality clinical evidence is needed to support clinical decision-making. |
|
|
|
|
|
|
|
